Teva Pharmaceutical Indus 株価情報 (NYSE: TEVA)

Teva Pharmaceutical Indus (NYSE:TEVA) 株価情報

Teva Pharmaceutical Indus

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Industries Ltd

TEVA PHARM INDUS LTD ORD by Teva Pharmaceutical Industries Ltd.

TEVANO SYS HLDGS INC by Tevano Systems Holdings Inc.

Tevano Systems Holdings Inc

News

ALVO

TEVA

Teva Pharmaceuticals And Alvotech Announce U.S. Availability of SELARSDI (Ustekinumab-aekn) Injection, A Biosimilar To Stelara For Treatment Of Psoriatic Arthritis, Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis, Pediatric Plaque Psoriasis And Pediatric Psoriatic Arthritis

WIIM

Teva shares are trading higher after the FDA accepted for review a Biologics License Application for AVT06, a proposed biosimilar to Eylea.

Biotech

Health Care

General

The FDA Has Accepted For Review A Biologics License Application For AVT06, Alvotech's Proposed Biosimilar To Teva Pharmaceuticals' Eylea (Aflibercept), A Biologic Used To Treat Eye Disorders, The Process To Obtain Regulatory Approval Is Anticipated To Be Completed In Q4 2025

Billionaire investor Stanley Druckenmiller&#8216;s family office Duquesne has divested his entire stake in Broadcom, simultaneously increasing his investments in major tech companies, as revealed in a recent 13-F filing.
What Happened: According to a recent&nbsp;SEC filing, Druckenmiller, a seasoned investor, sold all his shares of&nbsp;Broadcom Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) in the fourth quarter. This move comes on the heels of his total exit from Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), a competing chipmaker, a few months prior.
In the closing months of 2024, Druckenmiller significantly reduced his tech stock portfolio, selling his entire stakes in&nbsp;Microsoft Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>),&nbsp;Adobe Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) and&nbsp;Autodesk Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>). He also completely sold his stake in&nbsp;Starbucks Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) and his shares in insurance company&nbsp;Chubb Ltd.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>).
Despite these divestments, Druckenmiller increased his investments in several big tech companies in the same quarter, acquiring new positions in&nbsp;Alphabet Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>),&nbsp;Amazon.com Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Elon Musk&#8216;s electric vehicle manufacturer&nbsp;Tesla Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
Druckenmiller&#8217;s Duquesne also initiated new investments in United Airlines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NYSE">UAL</a>), Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>), Warner Bros. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NYSE">WBD</a>), Skechers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>), and Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
The most significant holding in his Duquesne Family Office remains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), the clinical genetic-testing company in which they held a stake since 2022. Natera holdings account for just over 15% of the portfolio. Meanwhile, the firm increased its stake in Teva Pharmaceuticals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) by nearly 6.3 times. 
SEE ALSO: <a href="https://www.benzinga.com/25/02/43649046/warner-bros-jinjiang-international-collaborate-for-harry-potter-studio-tour-in-shanghai">Warner Bros Announces Shanghai Harry Potter Studio Tour—Set To Be Four Times Larger Than London&#8217;s</a>
Why It Matters: Druckenmiller, who formerly managed hedge funds for George Soros, now manages his own wealth through the Duquesne Family Office, which has investments worth nearly $3.72 billion.
The billionaire investor&#8217;s latest moves follow his earlier divestments in AI stocks. During the third quarter of 2024, <a href="https://www.benzinga.com/markets/equities/24/12/42668157/stanley-druckenmiller-dumps-streets-hottest-ai-stocks-heres-what-the-billionaire-investor-is-betting-on-next">Druckenmiller sold all of its Nvidia shares and significantly reduced its Palantir holdings</a> by 95%. This occurred despite Nvidia and Palantir experiencing significant stock surges that year, with Nvidia&#8217;s stock increasing nearly 190% and Palantir&#8217;s shares gaining over 386%. 
The current quarter&#8217;s exit from Broadcom despite the stock surging more than 100% over the past year appears as a profit booking move. Meanwhile, other additions in big tech stocks show his growing confidence in the sector.
Druckenmiller added Tesla to its portfolio which surged over 83% in the past year. However, the stock plunged more than 16% over the last month, amid declining global sales, regulatory roadblocks in China, earnings disappointment, and Musk&#8217;s increasing political involvement. 
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/25/02/43772576/tesla-to-start-delivering-shanghai-made-refreshed-model-ys-next-week">Tesla&#8217;s Refreshed Model Y Rolls Off Shanghai Gigafactory, Deliveries To Start &#8216;Soon&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Markets

Tech

ADBE

ADSK

AMZN

AVGO

GOOGL

MSFT

NTRA

NVDA

SBUX

TSLA

Billionaire Investor Stanley Druckenmiller Dumps Broadcom, Bets Big On Tesla, Amazon And Other Big Tech Stocks In Q4

These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>WeRide Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) shares rocketed 97.62% after NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) disclosed a stake of 1.74 million shares in a 13F filing.</li>
<li>GDS Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) stock escalated 43.45%, probably after President Trump had reportedly postponed tariffs on packages under $800 from China. Additionally, optimism towards China&#8217;s DeepSeek AI model has also lifted stocks recently.</li>
<li>SpringWorks Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) shares jumped 42.58% after announcing Merck KGaA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MKGAF#OTC">MKGAF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MKKGY#OTC">MKKGY</a>) is in advanced <a href="https://www.benzinga.com//node/43631130" target="_blank" rel="noreferrer noopener">discussions to acquire the company</a>.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) shares increased 40.59%.</li>
<li>Sable Offshore Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) stock upped 39.09%.</li>
<li>GeneDx Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) shares rose 28.23%  after the company announced UltraRapid Whole Genome Sequencing, which will deliver actionable <a href="https://www.benzinga.com//node/43692155" target="_blank" rel="noreferrer noopener">results within 48 hours</a>.</li>
<li>VNET Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) stock upped 28.22%, probably amid a possible rebound after falling last week due to AI competition concerns related to China&#8217;s DeepSeek AI model.</li>
<li>Insperity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSP#NYSE">NSP</a>) stock increased 25.99% after the company reported better-than-<a href="https://www.benzinga.com//node/43590222" target="_blank" rel="noreferrer noopener">expected fourth-quarter results</a>.</li>
<li>CRISPR Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) stock grew 25.21% after the company reported better-than-<a href="https://www.benzinga.com//node/43639785" target="_blank" rel="noreferrer noopener">expected fourth-quarter financial results</a>. Several analysts raised the price <a href="https://www.benzinga.com/quote/crsp/analyst-ratings" target="_blank" rel="noreferrer noopener">forecast on the stock</a>.</li>
<li>Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) stock grew 24.01% after the company reached a settlement agreement with Teva Pharmaceutical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), resolving all patent <a href="https://www.benzinga.com//node/43601535" target="_blank" rel="noreferrer noopener">litigation related to its Auvelity product</a>. Several analysts raised <a href="https://www.benzinga.com/quote/axsm/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
</ol>
Photo via WeRide

Mid Cap

Movers

Trading Ideas

AXSM

CRSP

MKGAF

MKKGY

RXRX

SWTX

VNET

WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?

Investors with a lot of money to spend have taken a bearish stance on Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TEVA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Teva Pharmaceutical Indus.
This isn't normal.
The overall sentiment of these big-money traders is split between 12% bullish and 50%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $288,604, and 2 are calls, for a total amount of $143,091.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $15.0 to $17.0 for Teva Pharmaceutical Indus during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Teva Pharmaceutical Indus's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Teva Pharmaceutical Indus's whale trades within a strike price range from $15.0 to $17.0 in the last 30 days. 
<h3>Teva Pharmaceutical Indus 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739214939_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$3.15</td>
<td>$3.05</td>
<td>$3.05</td>
<td>$15.00</td>
<td>$91.2K</td>
<td>1.2K</td>
<td>301</td>
</tr>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$2.16</td>
<td>$2.06</td>
<td>$2.16</td>
<td>$17.00</td>
<td>$76.8K</td>
<td>10.7K</td>
<td>611</td>
</tr>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$1.28</td>
<td>$1.07</td>
<td>$1.28</td>
<td>$15.00</td>
<td>$74.2K</td>
<td>2.4K</td>
<td>592</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$0.52</td>
<td>$0.4</td>
<td>$0.51</td>
<td>$16.50</td>
<td>$51.8K</td>
<td>1.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$1.45</td>
<td>$1.38</td>
<td>$1.42</td>
<td>$17.00</td>
<td>$35.5K</td>
<td>15.3K</td>
<td>250</td>
</tr>
</tbody>
</table>

<h3>About Teva Pharmaceutical Indus</h3>
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
In light of the recent options history for Teva Pharmaceutical Indus, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Teva Pharmaceutical Indus Standing Right Now?</h3>
<ul>
<li>With a volume of 4,482,422, the price of TEVA is down -0.68% at $16.71. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 86 days.</li>
</ul>
<h3>Expert Opinions on Teva Pharmaceutical Indus</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $28.25.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Teva Pharmaceutical Indus, targeting a price of $27. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Teva Pharmaceutical Indus, maintaining a target price of $30. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Teva Pharmaceutical Indus, maintaining a target price of $26. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Teva Pharmaceutical Indus, which currently sits at a price target of $30. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Teva Pharmaceutical Indus options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Spotlight on Teva Pharmaceutical Indus: Analyzing the Surge in Options Activity

On Monday, Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) signed a settlement agreement with Teva Pharmaceuticals Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>).
The settlement resolves all patent litigation related to Axsome&#8217;s Auvelity (dextromethorphan HBr – <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43588347/axsome-therapeutics-announces-settlement-agreement-resolving-auvelity-dextromethorphan-hbr-bupropi" rel="noreferrer noopener">bupropion HCl) product</a>.
Auvelity is approved in the U.S. for major depressive disorder.
The litigation resulted from Teva submitting an Abbreviated New Drug Application to the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of Auvelity in the U.S. before the expiration of applicable Axsome patents.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42739705/axsome-reveals-data-from-alzheimers-studies-analyst-sees-hope-despite-mixed-trial-results" rel="noreferrer noopener">Axsome Reveals Data From Alzheimer&#8217;s Studies, Analyst Sees Hope Despite Mixed Trial Results</a>
Under the terms of the settlement agreement, Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric exclusivity is granted for Auvelity, or on or after September 30, 2038, if no pediatric exclusivity is granted.
The parties will terminate all ongoing litigation between Axsome and Teva regarding Auvelity patents pending in the U.S. District Court for the District of New Jersey.
In January, Axsome Therapeutics reported preliminary Auvelity net product sales are expected to be approximately $92.6 million and $291.4 million for the fourth quarter and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42940823/axsome-therapeutics-provides-preliminary-fourth-quarter-and-full-year-2024-net-revenue" rel="noreferrer noopener">full year of 2024, respectively</a>.
Recently, the FDA approved Axsome Therapeutics&#8217; Symbravo&nbsp;(meloxicam and rizatriptan) for the acute treatment of migraine with or <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43351848/axsome-therapeutics-announces-fda-approval-of-symbravo-meloxicam-and-rizatriptan-for-the-acute-tre" rel="noreferrer noopener">without aura in adults</a>.
&#8220;Axsome is our top pick for 2025,&#8221; William Blair writes. Analyst Myles Minter reiterates the Outperform rating based on favorable litigation settlement and clarity on Auvelity&#8217;s generic launch timing.
&#8220;We also remain impressed with the Auvelity launch, which showed 15% growth in revenue over the prior quarter and is annualizing about $370 million after two years of launch,&#8221; William Blair adds.
Axsome now has three commercial products with the approval of Symbravo for migraines. While investors are mainly watching Auvelity's rollout for depression and its potential use in Alzheimer's-related agitation, analyst Minter writes Symbravo's potential in treating acute migraines is being overlooked.
William Blair also views Axsome as a takeout candidate with Johnson &amp; Johnson buying Intra-Cellular Therapies Inc. <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal" rel="noreferrer noopener">for $14.6 billion</a>.
Needham analyst Ami Fadia reiterates Axsome Therapeutics with a Buy and maintains a <a target="_blank" href="https://www.benzinga.com/quote/AXSM/analyst-ratings" rel="noreferrer noopener">$133 price target</a>.
Price Action: AXSM stock is up 24.6% at $131.77 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43597173/whats-going-on-with-bristol-myers-squibb-stock-on-monday" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Bristol Myers Squibb Stock On Monday?</a></li>
</ul>
Photo: Courtesy of Ulf Wittrock via Shutterstock.

Analyst Color

Price Target

Reiteration

Legal

Analyst Ratings

Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'

<ul>
<li>The litigation resulted from submission by Teva of an Abbreviated New Drug Application to the FDA seeking approval to market a generic version of AUVELITY in the United States prior to the expiration of applicable Axsome patents.</li>
<li>Under the terms of the settlement agreement, Axsome will grant Teva a license to sell its generic version of AUVELITY beginning on or after March 31, 2039, if pediatric exclusivity is granted for AUVELITY, or on or after September 30, 2038, if no pediatric exclusivity is granted, subject to FDA approval and conditions and exceptions customary for agreements of this type. In accordance with the agreement, the parties will terminate all ongoing litigation between Axsome and Teva regarding AUVELITY patents pending in the U.S. District Court for the District of New Jersey.</li>
</ul>

Axsome Therapeutics Entered Into A Settlement Agreement With Teva Pharmaceuticals Resolving All Patent Litigation Related To Axsome's Auvelity (Dextromethorphan HBR – Bupropion HCL) Product

These twelve large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Manhattan Associates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) shares plummeted 27.92% after the company announced soft guidance for the 2025 fiscal year <a href="https://www.benzinga.com//node/43315362" target="_blank" rel="noreferrer noopener">and analysts lowered the price forecast</a>.</li>
<li>Vertiv Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) shares fell 20.02%. Melius Research analyst Scott Davis downgraded the company from Buy to Hold and <a href="https://www.benzinga.com/quote/vrt/analyst-ratings" target="_blank" rel="noreferrer noopener">announced a $125 price forecast</a>.</li>
<li>Comfort Systems USA, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) stock declined 19.74% following the launch of DeepSeek<a href="https://www.benzinga.com//node/43254923" target="_blank" rel="noreferrer noopener">, China&#8217;s open-source AI model</a>.</li>
<li>Deckers Outdoor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) shares slipped 18.33% after the company reported its <a href="https://www.benzinga.com//node/43356259" target="_blank" rel="noreferrer noopener">third-quarter financial results</a>. Several analysts <a href="https://www.benzinga.com/quote/deck/analyst-ratings" target="_blank" rel="noreferrer noopener">cut the price forecast</a>.</li>
<li>Teva Pharmaceutical Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) shares decreased 18.22% after it reported <a href="https://www.benzinga.com//node/43303023" target="_blank" rel="noreferrer noopener">fourth-quarter financial results</a>. Analysts <a href="https://www.benzinga.com/quote/teva/analyst-ratings" target="_blank" rel="noreferrer noopener">cut the price forecast</a>.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) lost 15.81% last week on <a href="https://www.benzinga.com//node/43220297" target="_blank" rel="noreferrer noopener">China&#8217;s DeepSeek sparking doubts</a> over GPU spending frenzy. Also, reports indicating Trump officials have discussed further curbing China sales weighed on the stock.</li>
<li>EMCOR Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EME#NYSE">EME</a>) stock fell 15.72%.</li>
<li>Venture Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) shares slipped 14.79%.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) lost 14.28% last week due to <a href="https://www.benzinga.com//node/43231443" target="_blank" rel="noreferrer noopener">China&#8217;s DeepSeek sparking </a>investor fears in U.S. semiconductor stocks.</li>
<li>United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) shares tumbled 14.13% after it reported mixed fourth-quarter results and analysts <a href="https://www.benzinga.com//node/43389661" target="_blank" rel="noreferrer noopener">trimmed the price forecast</a>.</li>
<li>Quanta Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) shares dipped 14.08%. Citigroup analyst Andrew Kaplowitz maintained a Buy rating and lowered <a href="https://www.benzinga.com/quote/pwr/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast from $394 to $371</a>.</li>
<li>Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) shares dropped 13.66% amid concerns about AI competition from China&#8217;s DeepSeek AI model, which <a href="https://www.benzinga.com//node/43254923" target="_blank" rel="noreferrer noopener">has weighed on AI-related sectors</a>.</li>
</ol>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/02/43423005/alibaba-ibm-and-duolingo-are-among-top-0large-cap-gainers-last-week-jan-27-jan-31-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Alibaba, IBM And Duolingo Are Among Top 0Large Cap Gainers Last Week (Jan 27-Jan 31): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Shutterstock

Large Cap

DECK

MANH

SMCI

NVIDIA, Teva Pharmaceutical And UPS Are Among Top Large Cap Losers Last Week (Jan 27-Jan 31): Are The Others In Your Portfolio?

UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) with a Buy and lowers the price target from $30 to $27.

UBS Maintains Buy on Teva Pharmaceutical Indus, Lowers Price Target to $27

Teva Pharmaceutical shares are trading lower after Barclays cut its price target on the stock from $28 to $26.

Investors with a lot of money to spend have taken a bullish stance on Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TEVA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Teva Pharmaceutical Indus.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 37%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $635,855, and 3 are calls, for a total amount of $149,140.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $16.0 to $21.0 for Teva Pharmaceutical Indus over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Teva Pharmaceutical Indus's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Teva Pharmaceutical Indus's substantial trades, within a strike price spectrum from $16.0 to $21.0 over the preceding 30 days.
<h3>Teva Pharmaceutical Indus 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738264541_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$3.1</td>
<td>$2.94</td>
<td>$2.95</td>
<td>$21.00</td>
<td>$295.1K</td>
<td>5.2K</td>
<td>3.0K</td>
</tr>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$0.77</td>
<td>$0.68</td>
<td>$0.77</td>
<td>$18.00</td>
<td>$180.1K</td>
<td>26.3K</td>
<td>2.4K</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$3.2</td>
<td>$3.15</td>
<td>$3.2</td>
<td>$16.00</td>
<td>$79.6K</td>
<td>434</td>
<td>279</td>
</tr>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$3.05</td>
<td>$2.95</td>
<td>$3.0</td>
<td>$21.00</td>
<td>$74.7K</td>
<td>5.2K</td>
<td>250</td>
</tr>
<tr>
<td>TEVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$0.52</td>
<td>$0.48</td>
<td>$0.52</td>
<td>$17.00</td>
<td>$52.0K</td>
<td>2.7K</td>
<td>3.5K</td>
</tr>
</tbody>
</table>

<h3>About Teva Pharmaceutical Indus</h3>
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Following our analysis of the options activities associated with Teva Pharmaceutical Indus, we pivot to a closer look at the company's own performance.
<h3>Teva Pharmaceutical Indus's Current Market Status</h3>
<ul>
<li>With a volume of 23,352,592, the price of TEVA is up 0.22% at $18.58. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 97 days.</li>
</ul>
<h3>Expert Opinions on Teva Pharmaceutical Indus</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $28.666666666666668.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from UBS persists with their Buy rating on Teva Pharmaceutical Indus, maintaining a target price of $30. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Teva Pharmaceutical Indus, maintaining a target price of $26. 
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on Teva Pharmaceutical Indus with a target price of $30. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Teva Pharmaceutical Indus with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Teva Pharmaceutical Indus Options Trading: A Deep Dive into Market Sentiment

Across the recent three months, 4 analysts have shared their insights on Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $28.5, along with a high estimate of $30.00 and a low estimate of $26.00. This current average has increased by 9.62% from the previous average price target of $26.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1738238412_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Teva Pharmaceutical Indus among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Teva Pharmaceutical Indus. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Teva Pharmaceutical Indus compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Teva Pharmaceutical Indus's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Teva Pharmaceutical Indus's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TEVA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Teva Pharmaceutical Indus analyst ratings.</a>
<h2>Get to Know Teva Pharmaceutical Indus Better</h2>
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
<h3>Teva Pharmaceutical Indus: Delving into Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Teva Pharmaceutical Indus's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 12.49%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teva Pharmaceutical Indus's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -10.09%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -7.03%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Teva Pharmaceutical Indus's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -1.05%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 3.18, caution is advised due to increased financial risk.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Teva Pharmaceutical Indus Stock

Barclays analyst Balaji Prasad maintains Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) with a Overweight and lowers the price target from $28 to $26.

Barclays Maintains Overweight on Teva Pharmaceutical Indus, Lowers Price Target to $26

<h3>Gainers</h3>
<ul>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares rose 76.9% to $0.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $20.3 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock rose 57.77% to $2.13. The market value of their outstanding shares is at $8.5 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock moved upwards by 28.32% to $0.99. The market value of their outstanding shares is at $2.2 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock increased by 16.41% to $1.56. The company's market cap stands at $6.0 million. </li>
<li>OKYO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>) shares increased by 13.89% to $1.18. The market value of their outstanding shares is at $39.9 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) stock moved upwards by 11.95% to $0.52. The company's market cap stands at $96.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) shares decreased by 26.2% to $0.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.8 million. </li>
<li>Zentalis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZNTL#NASDAQ">ZNTL</a>) shares decreased by 24.59% to $1.81. The company's market cap stands at $128.9 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock fell 19.3% to $0.05. The market value of their outstanding shares is at $5.1 million. </li>
<li>Pulmonx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) shares declined by 15.71% to $5.1. The company's market cap stands at $201.3 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock declined by 15.45% to $1.15. The market value of their outstanding shares is at $31.6 million. </li>
<li>Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) shares fell 10.55% to $19.26. The company's market cap stands at $21.8 billion. The company's, Q4 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BACK

EYEN

LUNG

OCEA

OKYO

SLXN

SXTP

TNXP

TRIB

ZNTL

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 1% on Wednesday.
The Dow traded down 0.16% to 44,778.55 while the NASDAQ fell 1% to 19,537.19. The S&amp;P 500 also fell, dropping, 0.54% to 6,034.67.
Check This Out: <a href="https://www.benzinga.com/25/01/43300989/jim-cramer-this-industrial-stock-is-absolutely-terrific-first-solar-is-very-inexpensive">Jim Cramer: This Industrial Stock Is &#8216;Absolutely Terrific&#8217;, First Solar Is &#8216;Very Inexpensive&#8217;</a>
Leading and Lagging Sectors Consumer staples shares surged by 0.7% on Wednesday.
In trading on Wednesday, information technology shares fell by 1.9%.
Top Headline
U.S. crude inventories climbed by 3.463 million barrels during the recent week, compared to market estimates of a 3.2 million-barrel gain, according to the Energy Information Administration.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Signing Day Sports, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGN#NYSE">SGN</a>) shares shot up 128% to $4.41. Signing Day Sports executed a stock purchase agreement to acquire majority of capital stock of Swifty Global.</li>
<li>Shares of Ranpak Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACK#NYSE">PACK</a>)got a boost, surging 30% to $7.47 after the company announced it has agreed to issue warrants for up to 18.72 million shares.</li>
<li>Nextracker Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) shares were also up, gaining 20% to $47.37 as the company reported better-than-expected third-quarter financial results and raised its FY25 GAAP EPS guidance on Tuesday.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Teva Pharmaceutical Industries Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) shares dropped 13% to $18.78 following fourth-quarter financial results.</li>
<li>Shares of Manhattan Associates, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NYSE">MANH</a>) were down 24% to $224.87 following soft FY25 guidance.</li>
<li>Packaging Corporation of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>) was down, falling 9% to $218.99 after the company reported mixed fourth-quarter financial results.</li>
</ul>
Commodities In commodity news, oil traded down 1.5% to $72.62 while gold traded up 0.1% at $2,768.60.
Silver traded up 1.8% to $31.425 on Wednesday, while copper rose 0.8% to $4.2800.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.50%, Germany's DAX 40 gained 0.97% and France's CAC 40 fell 0.32%. Spain's IBEX 35 Index rose 1.09%, while London's FTSE 100 rose 0.28%.
Asia Pacific Markets
Asian markets closed higher on Wednesday, with Japan's Nikkei 225 gaining 1.02% and India's BSE Sensex gaining 0.83%.
Economics
<ul>
<li>The U.S. trade deficit in goods increased to a record $122.11 billion in December versus a revised $103.5 billion gap in the prior month.</li>
<li>U.S. wholesale inventories declined by 0.5% month-over-month to $898 billion in December following a revised 0.1% fall in the previous month and versus market estimates of a 0.2% gain.</li>
<li>U.S. crude inventories climbed by 3.463 million barrels during the recent week, compared to market estimates of a 3.2 million-barrel gain, according to the Energy Information Administration.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43301090/how-to-earn-500-a-month-from-meta-platforms-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Meta Platforms Stock Ahead Of Q4 Earnings</a></li>
</ul>

Earnings

Eurozone

Commodities

PACK

Crude Oil Down 1.5%; Teva Pharmaceutical Shares Plummet

Caution dominates Wednesday's midday trading session in New York as investors anxiously await the Federal Open Market Committee decision <a href="https://www.benzinga.com/topic/interest-rates">at 2 p.m. ET</a>.
The Fed is widely expected to keep interest rates unchanged at 4.25%-4.5%. Market participants remain highly focused on any signals from Fed Chair Jerome Powell regarding the path forward for rate cuts.
The December meeting delivered a shock to markets, with Powell adopting a more hawkish tone than anticipated, suggesting that interest rates have moved closer to a neutral zone.
This FOMC meeting is also the first since Donald Trump's administration took office, fueling speculation over whether Powell will address questions about the president's pledge to &#8220;lower interest rates immediately.&#8221;
Major equity indices are little changed, with tech stocks under slight pressure as Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) fell 5%, weighing on the sector. Tech titans Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>) and Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) will report earnings after the close, with investors awaiting management clarity over the DeepSeek AI competitive threat.
Among sectors, financial stocks — tracked by the Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) — hit fresh record highs, while communication services are on pace for their eighth consecutive session of gains.
The dollar and Treasury yields remain mostly flat ahead of the Fed's announcement. Commodities are mixed, with gold and oil down 0.4% and 0.9%, respectively, while silver and copper rise 1.2% and 1.1%.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is up 1% to $102,300, potentially snapping a four-session losing streak.
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,901.37</td>
<td>0.1%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,285.29</td>
<td>-0.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,055.43</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,412.74</td>
<td>-0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:30 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent012925&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.2% lower to $603.11.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;is flat at $448.62.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) edged 0.2% lower to $520.88.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) is flat at $226.81.</li>
<li>The Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) is outperforming, up 0.8%; the Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) is lagging, down 0.9%.</li>
</ul>
Wednesday&#8217;s Stock Movers
<ul>
<li>T-Mobile US Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) soared nearly 8% in reaction to stronger-than-expected quarterly results.</li>
<li>Other stocks reacting to company earnings include Starbucks Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NYSE">SBUX</a>), up 6.7%, Chubb Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>), up 3%, F5 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>), up 13%, ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) up 3.6%, Danaher Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), down 9%, The Progressive Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>), up 1.4%, Automatic Data Processing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADP#NASDAQ">ADP</a>), up 2.9%, General Dynamics Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>), down 3.2%, Norfolk Southern Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>), up 3.1%, MSCI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>), down 3.9%, Nasdaq Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>), up 0.9%, Hess Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>), up 0.6% and Teva Pharmaceuticals Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), down 13.8%. </li>
<li>Major companies reporting earnings after the close other than Microsoft and Meta include Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), ServiceNow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>), International Business Machines Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>), Lam Research Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>), Raymond James Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>), Ameriprise Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>), Waste Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) and Las Vegas Sands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>). </li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43304027/deepseek-selloff-is-a-correction-not-start-of-sustained-bear-market-goldman-sachs">DeepSeek Selloff Is A Correction, Not Start Of &#8216;Sustained Bear Market&#8217;: Goldman Sachs</a></li>
</ul>
Illustration created using artificial intelligence via Midjourney.

Sector ETFs

Broad U.S. Equity ETFs

Federal Reserve

ETFs

$BTC

ASML

SPDR Dow Jones Industrial Average ETF Trust

FFIV

LRCX

MSCI

NDAQ

TMUS

Stocks Tick Down Ahead Of Fed Meeting, Nvidia Jitters Resume, Trump Media Rallies: What's Driving Markets Wednesday?

U.S. stocks traded mostly lower midway through trading, with the Nasdaq Composite falling more than 100 points on Wednesday.
The Dow traded up 0.02% to 44,859.42 while the NASDAQ fell 0.63% to 19,609.55. The S&amp;P 500 also fell, dropping, 0.31% to 6,048.95.
Check This Out: <a href="https://www.benzinga.com/25/01/43300989/jim-cramer-this-industrial-stock-is-absolutely-terrific-first-solar-is-very-inexpensive">Jim Cramer: This Industrial Stock Is &#8216;Absolutely Terrific&#8217;, First Solar Is &#8216;Very Inexpensive&#8217;</a>
Leading and Lagging Sectors Utilities shares surged by 0.8% on Wednesday.
In trading on Wednesday, information technology shares fell by 1.2%.
Top Headline
Corning Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) posted better-than-expected fourth-quarter financial results and also issued first-quarter core EPS guidance with a midpoint above estimates.
Core sales grew 18% year-on-year to $3.87 billion, beating the analyst consensus estimate of $3.76 billion. The Apple glass supplier's core EPS of 57 cents beat the analyst consensus estimate of 56 cents.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Signing Day Sports, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGN#NYSE">SGN</a>) shares shot up 226% to $6.32. Signing Day Sports executed a stock purchase agreement to acquire majority of capital stock of Swifty Global.</li>
<li>Shares of Ranpak Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACK#NYSE">PACK</a>)got a boost, surging 24% to $7.12 after the company announced it has agreed to issue warrants for up to 18.72 million shares.</li>
<li>Nextracker Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) shares were also up, gaining 24% to $49.14 as the company reported better-than-expected third-quarter financial results and raised its FY25 GAAP EPS guidance on Tuesday.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Teva Pharmaceutical Industries Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) shares dropped 14% to $18.53 following fourth-quarter financial results.</li>
<li>Shares of Manhattan Associates, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NYSE">MANH</a>) were down 24% to $224.51 following soft FY25 guidance.</li>
<li>Packaging Corporation of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>) was down, falling 10% to $216.62 after the company reported mixed fourth-quarter financial results.</li>
</ul>
Commodities In commodity news, oil traded down 0.4% to $73.47 while gold traded up 0.3% at $2,774.80.
Silver traded up 2.5% to $31.655 on Wednesday, while copper rose 0.8% to $4.2800.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.63%, Germany's DAX 40 gained 1.05% and France's CAC 40 fell 0.31%. Spain's IBEX 35 Index rose 0.92%, while London's FTSE 100 rose 0.44%.
Asia Pacific Markets
Asian markets closed higher on Wednesday, with Japan's Nikkei 225 gaining 1.02% and India's BSE Sensex gaining 0.83%.
Economics
<ul>
<li>The U.S. trade deficit in goods increased to a record $122.11 billion in December versus a revised $103.5 billion gap in the prior month.</li>
<li>U.S. wholesale inventories declined by 0.5% month-over-month to $898 billion in December following a revised 0.1% fall in the previous month and versus market estimates of a 0.2% gain.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43301090/how-to-earn-500-a-month-from-meta-platforms-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Meta Platforms Stock Ahead Of Q4 Earnings</a></li>
</ul>

Intraday Update

Nasdaq Down Over 100 Points; Corning Posts Upbeat Earnings

Teva Pharmaceutical Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) shares are trading lower Wednesday on the heels of the company&#8217;s fourth-quarter financial results. Here&#8217;s what <a href="https://www.benzinga.com/pressreleases/25/01/g43298150/teva-delivers-second-consecutive-year-of-growth-announces-strong-financial-results-in-fourth-quart">you need to know</a>.
What To Know: Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported fourth-quarter adjusted earnings of 71 cents per share, beating estimates of 70 cents per share. 
&#8220;Focusing on rigorous execution of our Pivot to Growth strategy throughout the year, we continued to achieve important milestones in each of its four pillars, including surpassing the&nbsp;outlook&nbsp;for our key innovative products, growing our generics business across all segments, and accelerating our early-stage innovative pipeline, including the positive Phase 2b results for our duvakitug (anti-Tl1A) asset,&#8221; said Richard Francis, president and CEO of Teva Pharmaceutical.
&#8220;These results pave the way for pivotal trials in Crohn&#8217;s disease and ulcerative colitis, as well as, potentially, other Immunological and fibrotic indications beyond, in collaboration with our partner, Sanofi.&#8221;
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/01/43298036/danaher-q4-eps-miss-expectations-amid-diagnostics-segment-lag">Danaher Q4: EPS Miss Expectations Amid Diagnostics Segment Lag</a>
Outlook: Teva Pharmaceutical expects full-year 2025 revenue to be in the range of $16.8 billion to $17.4 billion versus estimates of $17.05 billion. The company expects full-year adjusted earnings to be between $2.35 and $2.65 per share versus estimates of $2.79 per share. 
&#8220;In 2025, we anticipate further progress in our key innovative growth drivers, while also executing on our complex generics and biosimilars business, supported by new product launches. We are also excited to advance to Phase 3 trials for our duvakitug (anti-TL1A) asset,&#8221; Francis said. 
The company&#8217;s earnings guidance appears to be weighing on shares. Management is currently discussing the quarter on a conference call that kicked off at 8 a.m. ET.
TEVA Price Action: <a href="http://benzinga.com/quote/teva">Teva Pharmaceutical shares</a> were down 8.78% at $19.64 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of Teva Pharmaceutical.

Teva Pharmaceutical Stock Falls On Q4 Earnings: What's Going On?

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.4% on Wednesday.
Shares of Manhattan Associates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/quote/MANH/earnings">soft FY25 guidance.</a>
Manhattan Associates said it sees FY2025 adjusted earnings of $4.45 to $4.55 per share, versus market estimates of $4.91 per share. The company expects sales of $1.060 billion to 1.070 billion, versus projections of $1.14 billion.
Manhattan Associates shares dipped 23.4% to $225.92 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Globalstar, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#NYSE">GSAT</a>) shares dipped 21.5% to $1.4999 in pre-market trading.</li>
<li>LendingClub Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) fell 21% to $13.30 in pre-market trading following worse-than-expected reported fourth-quarter EPS results.</li>
<li>Avnet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVT#NASDAQ">AVT</a>) shares fell 7.4% to $48.56 in pre-market trading following weak quarterly earnings.</li>
<li>Teva Pharmaceutical Industries Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) fell 6.4% to $20.16 in pre-market trading following fourth-quarter reported financial results.</li>
<li>Victoria&#8217;s Secret &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) dipped 6.3% to $35.51 in pre-market trading. Victoria&#8217;s Secret announced that Chief Financial and Administrative Officer Timothy Johnson is retiring in June 2025 and Scott Sekella has been appointed Chief Financial Officer.</li>
<li>Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) fell 6.2% to $232.54 in pre-market trading after the company reported quarterly adjusted EPS below estimates..</li>
<li>American Axle &amp; Manufacturing Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXL#NYSE">AXL</a>) fell 6% to $5.47 in pre-market trading. American Axle &amp; Manufacturing and Dowlais announced plans to merge in a $1.44 billion cash-and-stock deal.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43263799/wall-streets-most-accurate-analysts-spotlight-on-3-tech-telecom-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Tech &amp; Telecom Stocks Delivering High-Dividend Yields</a></li>
</ul>

Pre-Market Outlook

GSAT

VSCO

Manhattan Associates, LendingClub And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Press Releases

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States

Teva Announces Collaboration to Commercialize Formycon's Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn's Disease

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Teva Pharmaceutical Indus

ニュース

パートナーシップ

ベンジンガ・グローバル